These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 11314939)
1. Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis. Dolan JT; Miltenburg DM; Granchi TS; Miller CC; Brunicardi FC Ann Surg Oncol; 2001 Apr; 8(3):227-33. PubMed ID: 11314939 [TBL] [Abstract][Full Text] [Related]
2. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Hejna M; Schmidinger M; Raderer M Ann Oncol; 2002 May; 13(5):653-68. PubMed ID: 12075733 [TBL] [Abstract][Full Text] [Related]
3. [The role of somatostatin analogues in the treatment of hypophyseal adenomas]. Losa M; Mortini P; Giovanelli M Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362 [TBL] [Abstract][Full Text] [Related]
4. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas]. Hansen CP; Knigge U Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299 [TBL] [Abstract][Full Text] [Related]
5. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Canobbio L; Cannata D; Miglietta L; Boccardo F Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848 [TBL] [Abstract][Full Text] [Related]
6. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183 [TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin agonists for treatment of acromegaly. Ben-Shlomo A; Melmed S Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials]. Igaz P Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137 [TBL] [Abstract][Full Text] [Related]
11. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133 [TBL] [Abstract][Full Text] [Related]
12. [Application of preparations--analogues of somatostatin in surgical pancreatology]. Kopchak VM; Kostylev MV; Kopchak KV; Egorova ON; Khomiak IV; Duvalko AV; Romaniv IaV; Pererva LA Klin Khir; 2008 Jan; (1):18-21. PubMed ID: 18610850 [TBL] [Abstract][Full Text] [Related]
13. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. de Herder WW; Lamberts SW Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981 [TBL] [Abstract][Full Text] [Related]
14. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029 [TBL] [Abstract][Full Text] [Related]
15. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824 [TBL] [Abstract][Full Text] [Related]
16. Octreotide as first-line treatment for women with metastatic breast cancer. Ingle JN; Kardinal CG; Suman VJ; Krook JE; Hatfield AK Invest New Drugs; 1996; 14(2):235-7. PubMed ID: 8913847 [TBL] [Abstract][Full Text] [Related]
17. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Colao A; Auriemma RS; Pivonello R Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466 [TBL] [Abstract][Full Text] [Related]
18. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Arnold R; Simon B; Wied M Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693 [TBL] [Abstract][Full Text] [Related]
19. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872 [TBL] [Abstract][Full Text] [Related]
20. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]